132 related articles for article (PubMed ID: 27157043)
1. In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.
Geissler K; Jäger E; Barna A; Sliwa T; Knöbl P; Schwarzinger I; Gisslinger H; Valent P
Eur J Haematol; 2016 Dec; 97(6):562-567. PubMed ID: 27157043
[TBL] [Abstract][Full Text] [Related]
2. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).
Padron E; Dezern A; Andrade-Campos M; Vaddi K; Scherle P; Zhang Q; Ma Y; Balasis ME; Tinsley S; Ramadan H; Zimmerman C; Steensma DP; Roboz GJ; Lancet JE; List AF; Sekeres MA; Komrokji RS;
Clin Cancer Res; 2016 Aug; 22(15):3746-54. PubMed ID: 26858309
[TBL] [Abstract][Full Text] [Related]
3. Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.
Francke S; Mies A; Meggendorfer M; Oelschlaegel U; Balaian E; Gloaguen S; Haferlach T; Ehninger G; Bornhäuser M; Platzbecker U
Leuk Lymphoma; 2017 May; 58(5):1271-1272. PubMed ID: 27659716
[No Abstract] [Full Text] [Related]
4. Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.
Geissler K; Ohler L; Födinger M; Virgolini I; Leimer M; Kabrna E; Kollars M; Skoupy S; Bohle B; Rogy M; Lechner K
J Exp Med; 1996 Oct; 184(4):1377-84. PubMed ID: 8879210
[TBL] [Abstract][Full Text] [Related]
5. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA; Dominguez-Viqueira W; Letson C; Balasis ME; Ball M; Kruer T; Zhang H; Lancet JE; List AF; Sekeres MA; Komrokji RS; Padron E
Clin Cancer Res; 2021 Nov; 27(22):6095-6105. PubMed ID: 34253584
[TBL] [Abstract][Full Text] [Related]
6. High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.
Sagaster V; Ohler L; Berer A; Kabrna E; Ofner P; Lechner K; Geissler K
Ann Hematol; 2004 Jan; 83(1):9-13. PubMed ID: 13680175
[TBL] [Abstract][Full Text] [Related]
7. Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Geissler K; Jäger E; Barna A; Gurbisz M; Graf T; Graf E; Nösslinger T; Pfeilstöcker M; Machherndl-Spandl S; Stauder R; Zebisch A; Sill H; Öhler L; Kusec R; Hörmann G; Valent P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842710
[TBL] [Abstract][Full Text] [Related]
8. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.
Padron E; Painter JS; Kunigal S; Mailloux AW; McGraw K; McDaniel JM; Kim E; Bebbington C; Baer M; Yarranton G; Lancet J; Komrokji RS; Abdel-Wahab O; List AF; Epling-Burnette PK
Blood; 2013 Jun; 121(25):5068-77. PubMed ID: 23632888
[TBL] [Abstract][Full Text] [Related]
9. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
[TBL] [Abstract][Full Text] [Related]
10. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo.
Ramshaw HS; Bardy PG; Lee MA; Lopez AF
Exp Hematol; 2002 Oct; 30(10):1124-31. PubMed ID: 12384142
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of granulocyte-macrophage colony formation in chronic myelomonocytic leukemia: a comparative study with other myelodysplastic and myeloproliferative disorders.
Yuo A; Miyazono K; Urabe A; Takaku F
Jpn J Cancer Res; 1990 Aug; 81(8):820-6. PubMed ID: 2118895
[TBL] [Abstract][Full Text] [Related]
12. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
13. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
14. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
16. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid in adult chronic myelomonocytic leukemia: results of a pilot study.
Cambier N; Wattel E; Menot ML; Guerci A; Chomienne C; Fenaux P
Leukemia; 1996 Jul; 10(7):1164-7. PubMed ID: 8683997
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.
Yee KW; Chen HW; Hedley DW; Chow S; Brandwein J; Schuh AC; Schimmer AD; Gupta V; Sanfelice D; Johnson T; Le LW; Arnott J; Bray MR; Sidor C; Minden MD
Invest New Drugs; 2016 Oct; 34(5):614-24. PubMed ID: 27406088
[TBL] [Abstract][Full Text] [Related]
19. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
